{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:59:36Z","timestamp":1790269176558,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.iotech.2026.101601","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:28:00Z","timestamp":1785770880000},"page":"101601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Germline BRCA1 pathogenic variants and T cell dysfunction"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6673-6604","authenticated-orcid":false,"given":"J.","family":"Kay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9904-4091","authenticated-orcid":false,"given":"M.A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-353X","authenticated-orcid":false,"given":"L.E.","family":"Lara Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.T.","family":"van Geelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-985X","authenticated-orcid":false,"given":"K.A.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-8104","authenticated-orcid":false,"given":"B.","family":"Virassamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5086-2544","authenticated-orcid":false,"given":"F.","family":"Caramia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.R.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Hun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-2511","authenticated-orcid":false,"given":"H.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Visvader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-5887","authenticated-orcid":false,"given":"P.J.","family":"Neeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.K.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-9171","authenticated-orcid":false,"given":"S.","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.iotech.2026.101601_bib1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41571-022-00672-8","article-title":"Is early-onset cancer an emerging global epidemic? Current evidence and future implications","volume":"19","author":"Ugai","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101601_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.iotech.2026.101601_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.iotech.2026.101601_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"issue":"10265","key":"10.1016\/j.iotech.2026.101601_bib5","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.iotech.2026.101601_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.iotech.2026.101601_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.iotech.2026.101601_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.iotech.2026.101601_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.trecan.2024.02.008","article-title":"The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments","volume":"10","author":"Rayson","year":"2024","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.iotech.2026.101601_bib10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.iotech.2026.101601_bib11","doi-asserted-by":"crossref","first-page":"5741","DOI":"10.1002\/jcp.27464","article-title":"Hereditary breast cancer; genetic penetrance and current status with BRCA","volume":"234","author":"Mahdavi","year":"2019","journal-title":"J Cell Physiol"},{"issue":"23","key":"10.1016\/j.iotech.2026.101601_bib12","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.iotech.2026.101601_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2006.01.006","article-title":"Histopathology of BRCA1- and BRCA2-associated breast cancer","volume":"59","author":"Honrado","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.iotech.2026.101601_bib14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41416-022-01888-2","article-title":"Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk","volume":"127","author":"Almekinders","year":"2022","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.iotech.2026.101601_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.iotech.2026.101601_bib16","article-title":"Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 exploratory analysis","volume":"7","author":"Loi","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.iotech.2026.101601_bib17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.iotech.2026.101601_bib18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.iotech.2026.101601_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/76950","article-title":"BRCA1 required for T cell lineage development but not TCR loci rearrangement","volume":"1","author":"Mak","year":"2000","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.iotech.2026.101601_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005852","article-title":"BRCA1 deficiency in mature CD8+ T lymphocytes impairs antitumor immunity","volume":"11","author":"Wu","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.iotech.2026.101601_bib21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","article-title":"Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy","volume":"1","author":"Samstein","year":"2021","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.iotech.2026.101601_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10549-022-06786-y","article-title":"Immune cells are increased in normal breast tissues of BRCA1\/2 mutation carriers","volume":"197","author":"Ogony","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"393","key":"10.1016\/j.iotech.2026.101601_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4922","article-title":"Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer","volume":"9","author":"Nolan","year":"2017","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.iotech.2026.101601_bib24","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/ijc.22915","article-title":"Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility","volume":"121","author":"Barwell","year":"2007","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.iotech.2026.101601_bib25","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.bjc.6602912","article-title":"Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers","volume":"94","author":"Kote-Jarai","year":"2006","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.iotech.2026.101601_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-016-0709-1","article-title":"Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation","volume":"18","author":"Baert","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"11","key":"10.1016\/j.iotech.2026.101601_bib27","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","article-title":"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage","volume":"95","author":"Yoshida","year":"2004","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.iotech.2026.101601_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.iotech.2026.101601_bib29","article-title":"An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation","volume":"060012","author":"Sergushichev","year":"2016","journal-title":"bioRxiv"},{"key":"10.1016\/j.iotech.2026.101601_bib30","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"issue":"2","key":"10.1016\/j.iotech.2026.101601_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.iotech.2026.101601_bib32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","article-title":"BRCA1 controls homology-directed DNA repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol Cell"},{"issue":"19","key":"10.1016\/j.iotech.2026.101601_bib33","doi-asserted-by":"crossref","first-page":"7178","DOI":"10.3390\/ijms21197178","article-title":"Prognostic significance of interferon-\u03b3 and its signaling pathway in early breast cancer depends on the molecular subtypes","volume":"21","author":"Heimes","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.iotech.2026.101601_bib34","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.3390\/cancers15184456","article-title":"Granzyme B expression in the tumor microenvironment as a prognostic biomarker for patients with triple-negative breast cancer","volume":"15","author":"Mizoguchi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.iotech.2026.101601_bib35","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.clbc.2020.06.011","article-title":"The role of immune cells in breast tissue and immunotherapy for the treatment of breast cancer","volume":"21","author":"Goff","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"8","key":"10.1016\/j.iotech.2026.101601_bib36","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.iotech.2026.101601_bib37","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41588-024-01688-9","article-title":"A single-cell atlas enables mapping of homeostatic cellular shifts in the adult human breast","volume":"56","author":"Reed","year":"2024","journal-title":"Nat Genet"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:01:09Z","timestamp":1790265669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S2590018826000201"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101601","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline BRCA1 pathogenic variants and T cell dysfunction","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101601"}}